EPI-7170 is a potent antagonist of the androgen receptor N-terminal domain (AR NTD), capable of inhibiting the transcriptional activity of both full-length androgen receptor (FL-AR) and androgen receptor splice variants (AR-Vs); it exhibits antitumor activity against enzalutamide-resistant castration-resistant prostate cancer (CRPC).